TRANSDERMAL ESTROGEN WITH A LEVONORGESTREL-RELEASING INTRAUTERINE-DEVICE FOR CLIMACTERIC COMPLAINTS - CLINICAL AND ENDOMETRIAL RESPONSES

被引:65
作者
RAUDASKOSKI, TH [1 ]
LAHTI, EI [1 ]
KAUPPILA, AJ [1 ]
APAJASARKKINEN, MA [1 ]
LAATIKAINEN, TJ [1 ]
机构
[1] OULU UNIV HOSP,DEPT PATHOL,SF-90220 OULU,FINLAND
关键词
HORMONE REPLACEMENT THERAPY; LEVONORGESTREL-RELEASING INTRAUTERINE DEVICE; TRANSDERMAL ESTRADIOL;
D O I
10.1016/0002-9378(95)90095-0
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: Our purpose was to study the effects of intrauterine release of a daily dose of 20 mu g levonorgestrel by an intrauterine device on climacteric symptoms, bleeding pattern, and endometrial histologic features in postmenopausal women receiving transdermal estrogen replacement therapy. STUDY DESIGN: Forty parous postmenopausal women were randomly allocated into two groups for 1 year: 20 women receiving a continuous transdermal daily dose of 50 mu g of estradiol had a levonorgestrel-releasing intrauterine contraceptive device inserted, and the control group of 20 women received a continuous oral dose of 2 mg of estradiol valerate and 1 mg of norethisterone acetate daily. The climacteric symptoms, bleeding patterns, endometrial thickness, and endometrial changes in biopsy samples were analyzed. Serum levels of estradiol in both groups and levonorgestrel levels in the intrauterine device group were also determined. RESULTS: Both treatment regimens effectively relieved climacteric symptoms. Spotting was more common in the intrauterine contraceptive device group than in the oral therapy group for the first 3 months. After that, the proportion of women without any bleeding was similar in both groups. Two patients in each group dropped out because of bleeding. CONCLUSION: These preliminary findings suggest that the levonorgestrel-releasing intrauterine contraceptive device is a useful alternative mode of progestin administration for certain selected women receiving estrogen replacement therapy.
引用
收藏
页码:114 / 119
页数:6
相关论文
共 16 条
[1]  
ANDERSSON K, 1992, OBSTET GYNECOL, V79, P963
[2]   ESTROGEN AND CORONARY HEART-DISEASE IN WOMEN [J].
BARRETTCONNOR, E ;
BUSH, TL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (14) :1861-1867
[3]  
CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31
[4]  
HARGROVE JT, 1989, OBSTET GYNECOL, V73, P606
[5]   THE ENDOMETRIAL STATUS OF WOMEN ON LONG-TERM CONTINUOUS COMBINED HORMONE REPLACEMENT THERAPY [J].
HAWTHORN, RJS ;
WALSH, D ;
HART, DM .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1991, 98 (09) :939-940
[6]   COMPARATIVE CLINICAL EVALUATION OF ESTROGENIC PREPARATIONS BY THE MENOPAUSAL AND AMENORRHEAL INDICES [J].
KUPPERMAN, HS ;
BLATT, MHG ;
WIESBADER, H ;
FILLER, W .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1953, 13 (06) :688-703
[7]   ENDOMETRIAL EFFECTS OF TRANSDERMAL ESTRADIOL NORETHISTERONE ACETATE [J].
LINDGREN, R ;
RISBERG, B ;
HAMMAR, M ;
BERG, G ;
PRYSEDAVIES, J .
MATURITAS, 1992, 15 (01) :71-78
[8]  
MAGOS AL, 1985, OBSTET GYNECOL, V65, P496
[9]   EVALUATION OF A CONTINUOUS ESTROGEN PROGESTOGEN REGIMEN FOR CLIMACTERIC COMPLAINTS [J].
MATTSSON, LA ;
CULLBERG, G ;
SAMSIOE, G .
MATURITAS, 1982, 4 (02) :95-102
[10]   MONITORING OF ESTROGEN REPLACEMENT THERAPY BY VAGINOSONOGRAPHY OF THE ENDOMETRIUM [J].
MEUWISSEN, JHJM ;
VANLANGEN, H ;
MORET, E ;
NAVARROMORQUECHO, I .
MATURITAS, 1992, 15 (01) :33-37